Lifeward Ltd.
Business
Lifeward Ltd. is a medical device company that designs, develops, and commercializes powered exoskeleton systems and anti-gravity rehabilitation equipment for physical rehabilitation and recovery across clinical, home, and community settings. The company's primary products are the ReWalk Personal and Rehabilitation Exoskeletons for spinal cord injury patients, the AlterG Anti-Gravity system for lower-limb rehabilitation, the ReStore soft exo-suit for stroke rehabilitation, and distributed MyoCycle cycles for functional electrical stimulation therapy. Lifeward serves rehabilitation clinics, hospitals, sports medicine facilities, and individual users primarily in the United States, Europe, and select international markets through direct sales and distributor networks.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 22 | 26 | 14 | 6 | 6 | |
| Cost of revenue | 14 | 17 | 9 | 4 | 3 | |
| Gross profit | 8 | 8 | 4 | 2 | 3 | |
| Research and development, net | 3 | 5 | 4 | 4 | 3 | |
| Sales and marketing | 14 | 18 | 14 | 10 | 7 | |
| General and administrative | 8 | 5 | 10 | 7 | 6 | |
| Impairment charges | 3 | 10 | 0 | 0 | — | |
| Total operating expenses | 28 | 38 | 28 | 21 | 16 | |
| Operating loss | −20 | −29 | −24 | −19 | −13 | |
| Financial (expense) income, net | −295,000 | 448,000 | 1 | — | 13,000 | |
| Loss before income taxes | −20 | −29 | −22 | −19 | −13 | |
| Taxes on income (benefit) | −55,000 | 43,000 | −12,000 | 467,000 | 94,000 | |
| Net loss | −20 | −29 | −22 | −20 | −13 | |
| Net loss per ordinary share, basic | −17.16 | −39.96 | −31.13 | −2.2 | −0.27 | |
| Net loss per ordinary share, diluted | −17.16 | −39.96 | −31.13 | −2.2 | −0.27 | |
| Weighted average number of shares used in computing net loss per ordinary share, basic | 1 | 724,272 | 710,941 | 9 | 48 | |
| Weighted average number of shares used in computing net loss per ordinary share, diluted | 1 | 724,272 | 710,941 | 9 | 48 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 7 | 28 | 68 | 88 | |
| Restricted cash | 240,000 | 197,000 | 0 | — | — | |
| Trade receivables, net of credit losses of $192 and $160, respectively | 6 | 6 | 3 | 1 | 585,000 | |
| Prepaid expenses and other current assets | 2 | 2 | 2 | 649,000 | 610,000 | |
| Inventories | 6 | 7 | 6 | 3 | 3 | |
| Total current assets | 16 | 21 | 39 | 73 | 93 | |
| Restricted cash and other long-term assets | 209,000 | 240,000 | 784,000 | 694,000 | 1 | |
| Operating lease right-of-use assets | 2 | 548,000 | 2 | 836,000 | 881,000 | |
| Property and equipment, net | 585,000 | 867,000 | 1 | 196,000 | 284,000 | |
| Goodwill | 5 | 8 | 8 | 0 | — | |
| Total long-term assets | 7 | 9 | 24 | 2 | 2 | |
| Total assets | 23 | 30 | 63 | 74 | 95 | |
| Trade payables | 6 | 5 | 5 | 2 | 1 | |
| Employees and payroll accruals | 1 | 1 | 2 | 1 | 1 | |
| Deferred revenue | 920,000 | 1 | 2 | 301,000 | 316,000 | |
| Convertible promissory notes | 3 | 0 | — | — | — | |
| Current maturities of operating leases liability | 425,000 | 858,000 | 1 | 564,000 | 641,000 | |
| Earnout liability | 0 | 608,000 | 576,000 | 0 | — | |
| Other current liabilities | 859,000 | 1 | 1 | 685,000 | 555,000 | |
| Total current liabilities | 12 | 10 | 12 | 5 | 4 | |
| Deferred revenues | 1 | 1 | 2 | 890,000 | 866,000 | |
| Non-current operating leases liability | 1 | 22,000 | 607,000 | 333,000 | 418,000 | |
| Other long-term liabilities | 61,000 | 67,000 | 58,000 | 66,000 | 45,000 | |
| Total long-term liabilities | 2 | 1 | 5 | 1 | 1 | |
| Total liabilities | 14 | 12 | 17 | 6 | 5 | |
| COMMITMENTS AND CONTINGENT LIABILITIES | — | — | — | — | — | |
| Ordinary share of NIS 1.75 par value-Authorized: 75,000,000 shares at December 31, 2025 and 25,000,000 shares at December 31, 2024; Issued: 1,572,319 and 781,854 shares at December 31, 2025 and December 31, 2024, respectively; Outstanding: 1,524,431 and 733,966 shares as of December 31, 2025 and December 31, 2024 respectively | 9 | 5 | 4 | 4 | 5 | |
| Additional paid-in capital | 287 | 282 | 281 | 280 | 279 | |
| Treasury Shares at cost, 47,888 ordinary shares at December 31, 2025 and December 31, 2024 | −3 | −3 | −3 | −2 | 0 | |
| Accumulated deficit | −285 | −265 | −236 | −214 | −194 | |
| Total shareholders' equity | 8 | 19 | 47 | 68 | 89 | |
| Total liabilities and shareholders' equity | 23 | 30 | 63 | 74 | 95 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 333,000 | 494,000 | 239,000 | 202,000 | 266,000 | |
| Amortization of intangible assets | 0 | 3 | 2 | 0 | 0 | |
| Impairment of intangible and tangible assets | 3 | 10 | 0 | 0 | — | |
| Share-based compensation | 743,000 | 1 | 1 | 993,000 | 833,000 | |
| Remeasurement of earnout liability | −608,000 | −3 | −315,000 | 0 | 0 | |
| Accrued interest | 442,000 | 0 | −11,000 | — | — | |
| Change in fair value of derivative liability | −197,000 | 0 | 0 | — | — | |
| Exchange rate fluctuations | −110,000 | −34,000 | −45,000 | 79,000 | 0 | |
| Trade receivables, net | −134,000 | −3 | −311,000 | −408,000 | 99,000 | |
| Prepaid expenses and other assets | 192,000 | 188,000 | −656,000 | 94,000 | 592,000 | |
| Operating lease right-of-use assets | 439,000 | 1 | 125,000 | — | — | |
| Inventories | 896,000 | −920,000 | −277,000 | −117,000 | 432,000 | |
| Trade payables | −347,000 | −47,000 | 1 | 566,000 | −884,000 | |
| Employees and payroll accruals | 110,000 | −702,000 | −14,000 | 140,000 | 275,000 | |
| Deferred revenues | −419,000 | −438,000 | −269,000 | −34,000 | 74,000 | |
| Operating lease liabilities | −731,000 | −1 | −144,000 | — | — | |
| Other liabilities | −304,000 | −150,000 | −829,000 | −153,000 | −391,000 | |
| Net cash used in operating activities | −17 | −22 | −21 | −18 | −11 | |
| Acquisition of a business, net of cash acquired | 0 | 0 | −18 | 0 | 0 | |
| Purchase of property and equipment | −16,000 | 0 | −81,000 | −25,000 | −47,000 | |
| Net cash used in investing activities | −16,000 | 0 | −18 | −25,000 | −47,000 | |
| Issuance of ordinary shares in a Registered Direct offering, net of issuance expenses in the amount of $558 | 4 | 0 | 0 | 0 | 28 | |
| Issuance of ordinary shares under at-the-market offering, net of issuance costs of $192 | 3 | 0 | 0 | — | — | |
| Issuance of ordinary shares in a public offering, net of issuance expenses in the amount of $432 | 2 | 0 | 0 | — | — | |
| Purchase of treasury shares | 0 | 0 | −992,000 | −3 | 0 | |
| Proceeds from short term loan | 1 | 0 | 0 | — | — | |
| Proceeds from bifurcated embedded derivatives | 2 | 0 | 0 | — | — | |
| Net cash provided by (used in) financing activities | 12 | 0 | −992,000 | −3 | 80 | |
| Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash | 110,000 | 34,000 | 45,000 | — | — | |
| Decrease in cash, cash equivalents, and restricted cash | −5 | −22 | −40 | −20 | 68 | |
| Classification of inventory to property and equipment, net | 35,000 | 404,000 | 481,000 | 67,000 | 32,000 | |
| Expenses related to offerings not yet paid | 473,000 | 0 | 0 | 142,000 | 0 | |
| ROU assets obtained from lease liabilities | 1 | 193,000 | 513,000 | 0 | 0 | |
| Cash paid (received) for income taxes | 36,000 | −7,000 | 126,000 | 113,000 | — | |
| Cash received from interest | 81,000 | 654,000 | 1 | 0 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Lifeward Ltd.'s CIK number?
Lifeward Ltd.'s SEC CIK number is 0001607962 (1607962). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Lifeward Ltd.'s SEC filings?
All of Lifeward Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Lifeward Ltd. last report earnings?
Lifeward Ltd. (LFWD) most recently filed an earnings 8-K with the SEC on May 15, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001178913-26-002727). This is Lifeward Ltd.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Lifeward Ltd.'s most recent earnings 8-K?
Lifeward Ltd.'s latest earnings 8-K (Item 2.02) was filed May 15, 2026 under accession 0001178913-26-002727. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Lifeward Ltd.'s latest earnings 8-K →
Look up any company's CIK number →